Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Hepregen Launches First Dual-Species HepatoPac™ DMPK Assay Kits

Published: Wednesday, September 25, 2013
Last Updated: Tuesday, September 24, 2013
Bookmark and Share
Rat and human liver cells on a single tissue culture plate designed for high efficiency data collection.

Hepregen Corporation has announced the commercial launch of the Company's first application-oriented, dual-species HepatoPac™ kit designed specifically for use in metabolite identification and profiling.

Each kit contains one standard 24-well tissue culture plate, half containing micro-patterned human hepatocytes, and the other half containing micro-patterned rat hepatocytes (available in Wistar-Hahn or Sprague-Dawley strains).

The hepatocytes on these plates from both species remain fully functional for up to two months. These unique dual-species kits provide customers with a plug-in-ready product, designed for use in evaluating metabolite production in a discovery or development setting, or in any case where a quick comparative answer is beneficial.

Dr. Vincent Zurawski, Hepregen's chief executive officer stated, "The incredible flexibility of our HepatoPac™ assay systems allows Hepregen to provide customers with a variety of cost-effective options for generating predictive and mechanistic data regarding metabolite identification and profiling."

He added, "The launch of this new dual-species product represents another way in which Hepregen is responding to customer needs. Data collected from two species simultaneously in a single experiment, especially when one or just a few compounds need to be evaluated rapidly, provides the highest efficiency approach to predicting likely in vivo metabolic outcomes in the laboratory."

Jack McGeehan, Hepregen's vice president of operations, added, "Our new dual-species product is a perfect fit for both smaller pharmaceutical companies that are testing a limited number of compounds, or DMPK groups within larger companies who support program teams in need of quick answers to questions regarding likely best approaches to preclinical evaluation. Our new HepatoPac™ kit can provide answers that will support clinical trial design or approaches to toxicokinetic testing."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SOLVO Biotechnology and Hepregen Execute Co-Marketing Agreement
Agreement provides for European sales of Hepregen's HepatoPac® and HepatoMune™ proprietary products by SOLVO and provision of services using these products.
Wednesday, June 24, 2015
Hepregen Announces Appointment of Dr. Michael Holsapple
Appointment adds respected leader in toxicology to Hepregen’s senior management team, reflecting ongoing commitment of Hepregen’s strategic investor, Battelle Memorial Institute.
Wednesday, August 07, 2013
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Vitamin A May Help Improve Pancreatic Cancer Chemotherapy
The addition of high doses of a form of vitamin A could help make chemotherapy more successful in treating pancreatic cancer, according to an early study by Queen Mary University of London (QMUL).
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
Non-Toxic Approach to Treating Variety of Cancers
A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently discovered a novel, non-toxic approach to treating a wide variety of cancers.
Making Injectable Medicine Safer
Researchers remove excess additives from drugs, which could reduce the odds of serious allergic reactions and other side effects.
An Old-New Weapon Against Emerging Chikungunya Virus
Researchers utilize existing drugs to interfere with host factors required for replication of Chikungunya virus.
Brazilian Zika Virus Strain Causes Birth Defects in Experimental Models
First direct experimental proof of causal effect, researchers say.
'Kidney on a Chip' Facilitates Safer Drug Dosing
University of Michigan researchers have used a "kidney on a chip" device to mimic the flow of medication through human kidneys and measure its effect on kidney cells.
Ketamine Metabolism Lifts Depression
NIH-funded team finds rapid-acting, non-addicting agent in mouse study.
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!